Arkema SA
PAR:AKE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
49.02
84.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
AKE
stock under the Base Case scenario is
110.7
EUR.
Compared to the current market price of 53.05 EUR,
Arkema SA
is
Undervalued by 52%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Arkema SA.
| ZA |
S
|
Sasol Ltd
JSE:SOL
|
|
| DE |
|
Basf Se
XETRA:BAS
|
|
| CN |
|
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
|
|
| IN |
|
Pidilite Industries Ltd
NSE:PIDILITIND
|
|
| ZA |
O
|
Omnia Holdings Ltd
JSE:OMN
|
|
| IN |
|
SRF Ltd
NSE:SRF
|
|
| JP |
|
Mitsubishi Chemical Holdings Corp
TSE:4188
|
|
| JP |
|
Showa Denko KK
TSE:4004
|
|
| JP |
M
|
Mitsubishi Chemical Group Corp
F:M3C0
|
|
| JP |
R
|
Resonac Holdings Corp
XMUN:SWD
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Arkema SA
Balance Sheet Decomposition
Arkema SA
| Current Assets | 4.4B |
| Cash & Short-Term Investments | 1.3B |
| Receivables | 1.8B |
| Other Current Assets | 1.3B |
| Non-Current Assets | 9.5B |
| Long-Term Investments | 58m |
| PP&E | 3.9B |
| Intangibles | 5.1B |
| Other Non-Current Assets | 455m |
| Current Liabilities | 1.6B |
| Accounts Payable | 935m |
| Other Current Liabilities | 681m |
| Non-Current Liabilities | 5.1B |
| Long-Term Debt | 3.6B |
| Other Non-Current Liabilities | 1.4B |
Free Cash Flow Analysis
Arkema SA
| EUR | |
| Free Cash Flow | EUR |
Earnings Waterfall
Arkema SA
|
Revenue
|
9.4B
EUR
|
|
Cost of Revenue
|
-7.6B
EUR
|
|
Gross Profit
|
1.8B
EUR
|
|
Operating Expenses
|
-1.2B
EUR
|
|
Operating Income
|
600m
EUR
|
|
Other Expenses
|
-390m
EUR
|
|
Net Income
|
210m
EUR
|
AKE Profitability Score
Profitability Due Diligence
Arkema SA's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Arkema SA's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
AKE Solvency Score
Solvency Due Diligence
Arkema SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Arkema SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AKE Price Targets Summary
Arkema SA
According to Wall Street analysts, the average 1-year price target for
AKE
is 64.96 EUR
with a low forecast of 47.47 EUR and a high forecast of 94.5 EUR.
Dividends
Current shareholder yield for
AKE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
AKE
stock under the Base Case scenario is
110.7
EUR.
Compared to the current market price of 53.05 EUR,
Arkema SA
is
Undervalued by 52%.